Study: Trexima better than Imitrex for migraines

04/5/2006 | Reuters

A pair of trials show taking Pozen's Trexima is more effective in treating migraine headaches than GlaxoSmithKline's Imitrex, the current leading drug for the problem. Trexima, which would be produced by GSK if the FDA approves a pending application, combines Imitrex and naproxen and provided pain relief after two hours in 57% to 65% of patients in trials, compared to 50% to 55% of patients taking Imitrex.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD